Skip to main content

Bard IVC Filter Trial: Potential Claims Clipped By Az. Judge

Bard IVC Filter Trial: Potential Claims Clipped By Az. Judge

Bard IVC Filter Trial: Potential Claims Clipped By Az. Judge

Introduction

An Arizona federal judge trimmed claims made by a plaintiff involved in the lawsuit against C.R. Bard’s IVC filter stating that the plaintiff cannot be awarded for the possibility of a heart arrhythmia condition likely to take place in the future. This is the third C.R. Bard bellwether trial over the alleged injuries caused by Bard’s IVC filters.

Judge David Campbell, presiding over the Bard multidistrict litigation (MDL), narrowed down the claims by a plaintiff, considering an expert's testimony who indicates an arrhythmia was likely to occur and not sure to occur. The judge granted in part a motion for judgment as a matter of law filed by C.R. Bard. The plaintiff was implanted with Bard’s G2X Blood vessel filter in 2011 to treat her deep-vein thrombosis and pulmonary embolism, which was eventually removed in 2014 as the device fractured and caused internal injuries to her.

More than 3,800 lawsuits are pending against the manufacturer following reports of device breakage and tissue perforation. A multidistrict litigation (MDL No. 2641; In Re: Bard IVC Filters Products Liability Litigation) was created on August 17, 2015, in the United States District Court District of Arizona, presided over by Judge David G. Campbell for centralized pretrial proceedings.

Last month, in an order issued, Senior Judge David Campbell, overlooking C.R. Bard IVC Filter litigation, denied a motion filed by a plaintiff to exclude evidence linked to the device instructions from the next bellwether trial.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

NC to Get $150M to Boost Opioid Treatment, Recovery

Categories: Opioids

North Carolina will receive an additional $150 million from Purdue Pharma and the Sackler family as part of a national $7.4 billion settlement related to the opioid

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!